Literature DB >> 19126421

Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Qingmei Jia1, Bai-Yu Lee, Daniel L Clemens, Richard A Bowen, Marcus A Horwitz.   

Abstract

Fransicella tularensis, the causative agent of tularemia, is in the top category (Category A) of potential agents of bioterrorism. To develop a safer vaccine against aerosolized F. tularensis, we have employed an attenuated Listeria monocytogenes, which shares with F. tularensis an intracellular and extraphagosomal lifestyle, as a delivery vehicle for F. tularensis antigens. We constructed recombinant L. monocytogenes (rLm) vaccines stably expressing seven F. tularensis proteins including IglC (rLm/iglC), and tested their immunogenicity and protective efficacy against lethal F. tularensis challenge in mice. Mice immunized intradermally with rLm/iglC developed significant cellular immune responses to F. tularensis IglC as evidenced by lymphocyte proliferation and CD4+ and CD8+ T-cell intracellular expression of interferon gamma. Moreover, mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126421      PMCID: PMC2654553          DOI: 10.1016/j.vaccine.2008.12.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  59 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus.

Authors:  Marina Rayevskaya; Natasha Kushnir; Fred R Frankel
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

Authors:  J Wayne Conlan; Hua Shen; Ann Webb; Malcolm B Perry
Journal:  Vaccine       Date:  2002-10-04       Impact factor: 3.641

4.  Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.

Authors:  M Fulop; P Mastroeni; M Green; R W Titball
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

Review 5.  Listeria as a vaccine vector.

Authors:  Kevin W Bruhn; Noah Craft; Jeff F Miller
Journal:  Microbes Infect       Date:  2007-05-07       Impact factor: 2.700

6.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

7.  Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors.

Authors:  Peter Lauer; Man Yin Nora Chow; Martin J Loessner; Daniel A Portnoy; Richard Calendar
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

8.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

9.  Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.

Authors:  Haroula Angelakopoulos; Katharina Loock; David M Sisul; Eric R Jensen; Jeff F Miller; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

10.  A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.

Authors:  Roger D Pechous; Travis R McCarthy; Nrusingh P Mohapatra; Shilpa Soni; Renee M Penoske; Nita H Salzman; Dara W Frank; John S Gunn; Thomas C Zahrt
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  27 in total

1.  Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Authors:  Luke C Kingry; Ryan M Troyer; Nicole L Marlenee; Helle Bielefeldt-Ohmann; Richard A Bowen; Alan R Schenkel; Steven W Dow; Richard A Slayden
Journal:  Microbes Infect       Date:  2010-11-09       Impact factor: 2.700

2.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

3.  Listeria-Vectored Vaccine Expressing the Mycobacterium tuberculosis 30-Kilodalton Major Secretory Protein via the Constitutively Active prfA* Regulon Boosts Mycobacterium bovis BCG Efficacy against Tuberculosis.

Authors:  Qingmei Jia; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

4.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

5.  Mice Housed at Elevated Vivarium Temperatures Display Enhanced T-cell Response and Survival to Francisella tularensis.

Authors:  Robert L Rubin
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

6.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

Review 7.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

8.  Rhombencephalitis Caused by Listeria monocytogenes in Humans and Ruminants: A Zoonosis on the Rise?

Authors:  Anna Oevermann; Andreas Zurbriggen; Marc Vandevelde
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-28

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

10.  Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Authors:  Ryan M Troyer; Katie L Propst; Jeff Fairman; Catherine M Bosio; Steven W Dow
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.